<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00401960</url>
  </required_header>
  <id_info>
    <org_study_id>0507008023</org_study_id>
    <nct_id>NCT00401960</nct_id>
  </id_info>
  <brief_title>Daptomycin as an Adjuvant Agent in the Treatment of Enterococcal Native Valve Endocarditis.</brief_title>
  <official_title>Open Label Study to Assess the Efficacy and Safety of Daptomycin in Combination With Anti-Cell Wall Active Therapy in the Treatment of Enterococcal Endocarditis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Weill Medical College of Cornell University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Weill Medical College of Cornell University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to determine the safety and efficacy of daptomycin when used as an
      adjuvant agent to standard care in the treatment of proven native valve Enterococcal
      endocarditis. Patients with this disease will be offered the option of receiving daptomycin
      at a dose of 8 milligrams/kilogram/day in addition to the antibiotics they are already
      receiving. The hypothesis of this study is that daptomycin added to standard therapy for
      Enterococcal endocarditis is safe and efficacious.

      Patients who receive daptomycin + standard therapy will be compared to patients who receive
      standard therapy alone with respect to the following outcomes:

        1. Safety.

             1. The frequency of any Grade 3 or 4 toxicity (DAIDS scale) will be measured.

             2. The frequency of muscle toxicity or renal toxicity, as determined by predefined
                criteria.

        2. Efficacy.

             1. Clinical efficacy.

                  -  Time to clearance of bacteremia

                  -  Cure at 6 weeks following completion of antibiotic therapy

                  -  Mortality at 6 weeks following completion of antibiotic therapy

             2. Microbiologic efficacy.

                  -  Peak and trough serum bactericidal titers

                  -  The minimum bactericidal concentration of Enterococci to daptomycin

      We expect to enroll 40 patients over 2 years.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    inadequate enrollment
  </why_stopped>
  <start_date>September 2006</start_date>
  <completion_date type="Actual">October 2008</completion_date>
  <primary_completion_date type="Actual">October 2008</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Any Grade 3 or 4 Toxicity (DAIDS Scale)</measure>
    <time_frame>weekly</time_frame>
    <description>Number of Participants any Grade 3 or 4 toxicity (DAIDS scale); please see adverse event table for details</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Muscle Toxicity or Renal Toxicity, as Determined by Predefined Criteria</measure>
    <time_frame>weekly</time_frame>
    <description>Number of Participants with creatine kinase elevation &gt; 3x upper limit of normal or elevations of serum Cr &gt;= 30% above baseline</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">6</enrollment>
  <condition>Endocarditis, Bacterial</condition>
  <arm_group>
    <arm_group_label>Daptomycin adjunctive group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with enterococcal endocarditis who elect to receive daptomycin at a dose of 8 milligrams/kilogram/day in addition to the antibiotics they are already receiving</description>
  </arm_group>
  <arm_group>
    <arm_group_label>standard of care</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Patients with enterococcal endocarditis who elect to receive standard of care therapy as prescribed by their primary physician</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Daptomycin</intervention_name>
    <description>daptomycin at a dose of 8 milligrams/kilogram/day in addition to the antibiotics they are already receiving for native valve enterococcal endocarditis</description>
    <arm_group_label>Daptomycin adjunctive group</arm_group_label>
    <other_name>Cubicin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 18 or over

          -  Definite Enterococcal endocarditis, as defined by modified Duke criteria

          -  Able to complete follow-up 3 and 6 weeks following completion of intravenous
             antibiotic therapy

        Exclusion Criteria:

          -  Pregnancy or breast feeding

          -  Creatine phosphokinase levels over two times the upper limit of normal

          -  Renal insufficiency or dialysis requirement.

          -  Presence of chronic indwelling bloodstream catheters or foreign body devices suspected
             as primary or secondary sites of enterococcal infection unamenable to removal or
             replacement

          -  Inability to discontinue or abstain from use of a HMG CoA reductase inhibitor during
             the study period.

          -  Hypersensitivity to any of the study medications.

          -  Any condition that, in the investigator's opinion, may interfere with protocol
             compliance including, but not limited to, active substance abuse and/or dementia.

          -  Prosthetic valve endocarditis
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kyu Y Rhee, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Weill Medical College of Cornell University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>NewYork-Presbyterian Hospital, Weill Cornell Campus</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 20, 2006</study_first_submitted>
  <study_first_submitted_qc>November 20, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 22, 2006</study_first_posted>
  <results_first_submitted>December 29, 2016</results_first_submitted>
  <results_first_submitted_qc>April 6, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">May 3, 2017</results_first_posted>
  <last_update_submitted>April 6, 2017</last_update_submitted>
  <last_update_submitted_qc>April 6, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 3, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Weill Medical College of Cornell University</investigator_affiliation>
    <investigator_full_name>Rhee, Kyu Y.</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <keyword>Enterococcus</keyword>
  <keyword>Daptomycin</keyword>
  <keyword>Endocarditis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Endocarditis</mesh_term>
    <mesh_term>Endocarditis, Bacterial</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Daptomycin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>This was a pilot single arm study, for which IPD are not pertinent</ipd_description>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Adjunctive Daptomycin Group</title>
          <description>please see study description for study enrollment</description>
        </group>
        <group group_id="P2">
          <title>Standard of Care Group</title>
          <description>as per study description</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>see study inclusion criteria</population>
      <group_list>
        <group group_id="B1">
          <title>Adjunctive Daptomycin Group</title>
          <description>please see study description for study enrollment</description>
        </group>
        <group group_id="B2">
          <title>Standard of Care Group</title>
          <description>as per study description</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="5"/>
            <count group_id="B2" value="1"/>
            <count group_id="B3" value="6"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="69" lower_limit="31" upper_limit="88"/>
                    <measurement group_id="B2" value="74" lower_limit="74" upper_limit="74"/>
                    <measurement group_id="B3" value="70" lower_limit="31" upper_limit="88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Any Grade 3 or 4 Toxicity (DAIDS Scale)</title>
        <description>Number of Participants any Grade 3 or 4 toxicity (DAIDS scale); please see adverse event table for details</description>
        <time_frame>weekly</time_frame>
        <population>Study terminated due to insufficient enrollment; therefore data not sufficient for planned analysis</population>
        <group_list>
          <group group_id="O1">
            <title>Adjunctive Daptomycin Group</title>
            <description>please see study description for study enrollment</description>
          </group>
          <group group_id="O2">
            <title>Standard of Care Group</title>
            <description>as per study description</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Any Grade 3 or 4 Toxicity (DAIDS Scale)</title>
          <description>Number of Participants any Grade 3 or 4 toxicity (DAIDS scale); please see adverse event table for details</description>
          <population>Study terminated due to insufficient enrollment; therefore data not sufficient for planned analysis</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Muscle Toxicity or Renal Toxicity, as Determined by Predefined Criteria</title>
        <description>Number of Participants with creatine kinase elevation &gt; 3x upper limit of normal or elevations of serum Cr &gt;= 30% above baseline</description>
        <time_frame>weekly</time_frame>
        <population>study terminated due to inadequate enrollment; therefore data not sufficient for planned analysis</population>
        <group_list>
          <group group_id="O1">
            <title>Daptomycin Adjunctive Group</title>
            <description>Patients with enterococcal endocarditis who elect to receive daptomycin at a dose of 8 milligrams/kilogram/day in addition to the antibiotics they are already receiving
Daptomycin: daptomycin at a dose of 8 milligrams/kilogram/day in addition to the antibiotics they are already receiving for native valve enterococcal endocarditis</description>
          </group>
          <group group_id="O2">
            <title>Standard of Care</title>
            <description>Patients with enterococcal endocarditis who elect to receive standard of care therapy as prescribed by their primary physician</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Muscle Toxicity or Renal Toxicity, as Determined by Predefined Criteria</title>
          <description>Number of Participants with creatine kinase elevation &gt; 3x upper limit of normal or elevations of serum Cr &gt;= 30% above baseline</description>
          <population>study terminated due to inadequate enrollment; therefore data not sufficient for planned analysis</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Elevated serum creatinine &gt;= 30% above baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Elevate serum creatine kinase &gt; 3X ULN</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>2 years; however, study terminated due to lack of eligible study participants</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Adjunctive Daptomycin Group</title>
          <description>please see study description for study enrollment</description>
        </group>
        <group group_id="E2">
          <title>Standard of Care Group</title>
          <description>as per study description</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>death</sub_title>
                <description>uncontrolled progression of underlying CLL</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>hemopericardium</sub_title>
                <description>underlying rheumatic heart disease and congestive heart failure; underlying conduction disorder S/P pacemekaer; both deemed unrelated to antibiotics</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="5"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>death</sub_title>
                <description>nosocomial Serratia pneumonia</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Cr elevation</sub_title>
                <description>day 9 of combination ABX with ampicillin, gentamicin, daptomycin- possibly related to daptomycin</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>study terminated due to insufficient enrollment; data therefore not analyzed</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>K Rhee</name_or_title>
      <organization>Weill Medical College</organization>
      <phone>6469626224</phone>
      <email>kyr9001@med.cornell.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

